Endometrial Cancer Clinical Trials in Madrid
25 recruitingMadrid, Spain
Showing 1–20 of 25 trials
Recruiting
Phase 1
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
Advanced Relapsed or Refractory Germ Cell TumoursAdvanced Relapsed or Refractory Endometrial CancerAdvanced Relapsed or Refractory Ovarian Cancer
Boehringer Ingelheim187 enrolled13 locationsNCT07306559
Recruiting
Phase 1Phase 2
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Ovarian CancerEndometrial CancerLung Adenocarcinoma+1 more
AstraZeneca506 enrolled60 locationsNCT05797168
Recruiting
Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Endometrial Cancer
Merck Sharp & Dohme LLC1,123 enrolled253 locationsNCT06952504
Recruiting
Phase 1Phase 2
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Breast CancerOvarian CancerEndometrial Cancer+2 more
AstraZeneca460 enrolled67 locationsNCT05123482
Recruiting
Phase 2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+11 more
Daiichi Sankyo740 enrolled85 locationsNCT06172478
Recruiting
Phase 1Phase 2
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Endometrial CancerRecurrent Ovarian CancerLow Grade Serous Ovarian Cancer+3 more
Regeneron Pharmaceuticals890 enrolled52 locationsNCT03564340
Recruiting
Phase 3
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Endometrial Cancer
AstraZeneca600 enrolled250 locationsNCT06989112
Recruiting
Phase 1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Gastric CancerEndometrial CancerHepatocellular Carcinoma+5 more
Seagen, a wholly owned subsidiary of Pfizer714 enrolled61 locationsNCT05208762
Recruiting
Phase 2
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Ovarian CancerEndometrial CancerFallopian Tube Cancer+1 more
Corcept Therapeutics270 enrolled49 locationsNCT06906341
Recruiting
Phase 2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Colorectal, CancerGastric CancerBiliary Tract Cancer+4 more
AstraZeneca454 enrolled95 locationsNCT05489211
Recruiting
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
Pancreatic CancerBiliary Tract CancerOvarian Cancer+3 more
AstraZeneca105 enrolled27 locationsNCT06973161
Recruiting
Phase 1Phase 2
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Ovarian CancerEndometrial CancerMetastatic Cancer+6 more
Artios Pharma Ltd442 enrolled79 locationsNCT04657068
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 1
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Breast CancerEndometrial CancerAdvanced Solid Tumor+2 more
Alterome Therapeutics, Inc.110 enrolled51 locationsNCT06533059
Recruiting
Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study
FIGO Grade 1 Endometrial Endometrioid AdenocarcinomaFIGO Grade 2 Endometrial Endometrioid AdenocarcinomaStage IA1 Endometrial Cancer FIGO 2023+1 more
Mayo Clinic212 enrolled20 locationsNCT06689956
Recruiting
Phase 1
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Breast CancerTriple-Negative Breast CancerEsophageal Cancer+9 more
SystImmune Inc.470 enrolled39 locationsNCT05983432
Recruiting
Phase 1
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Endometrial CancerMetastatic Solid TumorSolid Tumor, Adult+4 more
Sairopa B.V.130 enrolled7 locationsNCT05856981
Recruiting
Phase 1Phase 2
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Ovarian CancerEndometrial CancerPrimary Peritoneal Cancer+1 more
Regeneron Pharmaceuticals612 enrolled24 locationsNCT04590326
Recruiting
Phase 1Phase 2
A Beta-only IL-2 ImmunoTherapY Study
Triple-Negative Breast CancerEsophageal CancerGastric Cancer+34 more
Medicenna Therapeutics, Inc.115 enrolled27 locationsNCT05086692
Recruiting
Phase 1Phase 2
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Endometrial CancerAdvanced Solid TumorDiffuse Large B Cell Lymphoma+5 more
Novartis Pharmaceuticals275 enrolled60 locationsNCT04104776